Gedea Biotech: € 50k

Gedea has developed a vaginal tablet that contains the natural substance Glucono-δ-lactone (GDA), which switches Candida towards a benign yeast form, restores vaginal pH and disrupts the Candida and bacteria biofilm without causing treatment resistance. Gedea Biotech has been granted EUR 50k from SME Instrument Phase 1. GAEU’s team at Horizon 2020 Centre of Excellence wrote the proposal.

MORE REFERENCES

FOLLOW US